IL2 lysate

Human IL2 HEK293 Overexpression Lysate

• Applications: Western Blot
• Synonyms: IL2; Human IL2 HEK293 Overexpression Lysate; Human IL2 HEK293 Cell Lysate (WB positive control); Human IL-2 Overexpression Lysate; Human Interleukin-2 Overexpression Lysate; Human lymphokine Overexpression Lysate; Human TCGF Overexpression Lysate; interleukin 2; IL2 lysate

• Host: HEK293 Cells
• Form/Format: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF.; 1 X Sample Buffer (1 X modified RIPA buffer+1 X SDS loading buffer).

• Applicable Applications for IL2 lysate: Western Blot (WB)
• Species: Human
• Sequence Information: A DNA sequence encoding the human IL2 (NP_000577.2)(Met1-Thr153) was expressed with a polyhistidine tag at the C-terminus.
• Preparation Method: Cell lysate was prepared by homogenization in ice-cold modified RIPA Lysis Buffer with cocktail of protease inhibitors (Sigma). Cell debris was removed by centrifugation. Protein concentration was determined by Bradford assay (protein assay, Microplate Standard assay). The cell lysate was boiled for 5 min in 1 x SDS loading buffer (50mM Tris-HCl pH6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Recommend Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.; 2. Re-dissolve the pellet using 200uL pure water and boil for 2-5 min.; 3. Store the lyophilized cell lysate at 4 degree C. After re-dissolution, recommend to aliquot it into smaller quantities and store at -80 degree C.
• Preparation and Storage: Store at 4 degree C for up to twelve months from date of receipt. After re-dissolution, aliquot and store at -80 degree C for up to twelve months. Avoid repeated freeze-thaw cycles.

Related Product Information for IL2 lysate

Description: This Human IL2 overexpression lysate was created in HEK293 Cells and intented for use as a Western blot (WB) positive control. Purification of IL2 protein from the overexpression lysate was verified.

Background: Interleukin-2, also known as a T-cell growth factor, TCGF, Aldesleukin, and IL2, is a secreted protein that belongs to the IL-2 family. Interleukin-2/IL-2 was the first interleukin molecule to be discovered. Interleukin-2/IL-2 molecule was first purified to homogeneity by immunoaffinity chromatography by Kendall Smith and his team at Dartmouth Medical School. Interleukin-2/IL-2 was also the first cytokine shown to mediate its effects via a specific IL-2 receptor, and it was also the first interleukin to be cloned and expressed from a complementary DNA (cDNA) library. Interleukin-2/IL-2 was designated number 2 because Smith's data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells).
Interleukin-2/IL-2 is produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Interleukin-2/IL-2 is normally produced by the body during an immune response. When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of Interleukin-2/IL-2 and the expression of IL-2 receptors IL-2R. The IL-2/IL-2R interaction then stimulates the growth, differentiation, and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes. Interleukin-2/IL-2 can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. The World Reference Standard for Interleukin-2/IL-2 is produced by the National Institute of Biological Standards and Control in the UK. A recombinant form of Interleukin-2/IL-2 for clinical use is manufactured by Chiron Corporation with the brand name Proleukin. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of Interleukin-2/IL-2 in HIV therapy is ineffective.

Product Categories/Family for IL2 lysate

Neuroinflammation; Common G-Chain signaling pathway

References

Smith KA, et al.,1980, J. Exp. Med.151 (6): 1551-6. Smith KA, et al.,1980, Nature. 287 (5785): 853-5. Taniguchi T, et al.,1983, Nature. 302 (5906): 305. Cantrell DA, et al.,1984, Science. 224 (4655): 1312-6. Smith KA, et al.,1988, Science. 240 (4856): 1169-76. Wang X. et al., 2005, Science 310:1159-63. Stauber D.J. et al., 2006, Proc. Natl. Acad. Sci. USA. 103: 2788-93.